International Journal for Parasitology: Drugs and Drug Resistance (Apr 2017)

A novel in vitro image-based assay identifies new drug leads for giardiasis

  • Christopher J.S. Hart,
  • Taylah Munro,
  • Katherine T. Andrews,
  • John H. Ryan,
  • Andrew G. Riches,
  • Tina S. Skinner-Adams

DOI
https://doi.org/10.1016/j.ijpddr.2017.01.005
Journal volume & issue
Vol. 7, no. 1
pp. 83 – 89

Abstract

Read online

Giardia duodenalis is an intestinal parasite that causes giardiasis, a widespread human gastrointestinal disease. Treatment of giardiasis relies on a small arsenal of compounds that can suffer from limitations including side-effects, variable treatment efficacy and parasite drug resistance. Thus new anti-Giardia drug leads are required. The search for new compounds with anti-Giardia activity currently depends on assays that can be labour-intensive, expensive and restricted to measuring activity at a single time-point. Here we describe a new in vitro assay to assess anti-Giardia activity. This image-based assay utilizes the Perkin-Elmer Operetta® and permits automated assessment of parasite growth at multiple time points without cell-staining. Using this new approach, we assessed the “Malaria Box” compound set for anti-Giardia activity. Three compounds with sub-μM activity (IC50 0.6–0.9 μM) were identified as potential starting points for giardiasis drug discovery.

Keywords